Canada - TSX-V:GSD - CA2518348008 - Common Stock
The current stock price of GSD.CA is 0.13 CAD. In the past month the price decreased by -13.33%. In the past year, price decreased by -13.33%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
BHC.CA | BAUSCH HEALTH COS INC | 1.8 | 3.49B | ||
TLRY.CA | TILRAY BRANDS INC | N/A | 1.83B | ||
CRON.CA | CRONOS GROUP INC | 51 | 1.37B | ||
DHT-UN.CA | DRI HEALTHCARE TRUST | 6.92 | 821.23M | ||
GUD.CA | KNIGHT THERAPEUTICS INC | N/A | 615.84M | ||
DHT-U.CA | DRI HEALTHCARE TRUST | 4.89 | 580.05M | ||
WEED.CA | CANOPY GROWTH CORP | N/A | 484.32M | ||
HITI.CA | HIGH TIDE INC | N/A | 439.75M | ||
CPH.CA | CIPHER PHARMACEUTICALS INC | 26.62 | 431.45M | ||
TSND.CA | TERRASCEND CORP | N/A | 406.71M | ||
ACB.CA | AURORA CANNABIS INC | N/A | 391.50M | ||
OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 330.45M |
Devonian Health Group, Inc. is a pharmaceutical company, which engages in the development of botanical drugs. The company is headquartered in Montmagny, Quebec and currently employs 6 full-time employees. The company went IPO on 2014-09-09. The company specializes in the development of drugs for various autoimmune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. The company is developing prescription drugs for the treatment of inflammatory autoimmune diseases, including but not limited to, ulcerative colitis and atopic dermatitis. The company is also involved in the development of cosmeceutical products, leveraging the same proprietary approach employed with their pharmaceutical offerings. Its flagship product, Thykamine, is a pharmaceutical product issued from its SUPREX platform, for the prevention and treatment of health problems related to inflammation and oxidative stress, including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune diseases. Its cosmeceutical products include R-Spinasome and Purgenesis. Its subsidiary, Altius Healthcare Inc., sells prescription pharmaceutical products.
DEVONIAN HEALTH GROUP INC
360 rue des Entrepreneurs
Montmagny QUEBEC G5V 4T1 CA
CEO: Andre P. Boulet
Employees: 7
Phone: 15142487509
The current stock price of GSD.CA is 0.13 CAD. The price decreased by -23.53% in the last trading session.
The exchange symbol of DEVONIAN HEALTH GROUP INC is GSD and it is listed on the TSX Venture Exchange exchange.
GSD.CA stock is listed on the TSX Venture Exchange exchange.
DEVONIAN HEALTH GROUP INC (GSD.CA) has a market capitalization of 21.32M CAD. This makes GSD.CA a Nano Cap stock.
DEVONIAN HEALTH GROUP INC (GSD.CA) currently has 7 employees.
DEVONIAN HEALTH GROUP INC (GSD.CA) has a support level at 0.11 and a resistance level at 0.17. Check the full technical report for a detailed analysis of GSD.CA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GSD.CA does not pay a dividend.
DEVONIAN HEALTH GROUP INC (GSD.CA) will report earnings on 2025-11-27.
DEVONIAN HEALTH GROUP INC (GSD.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.03).
ChartMill assigns a fundamental rating of 3 / 10 to GSD.CA. GSD.CA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months GSD.CA reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS decreased by -60.37% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -22.47% | ||
ROE | -58.41% | ||
Debt/Equity | 0.01 |